Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-3.82m
- Incorporated--
- Employees43.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttp://www.oryzon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maat Pharma SA | 2.23m | -19.72m | 102.16m | 50.00 | -- | 4.17 | -- | 45.85 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Scope Fluidics SA | 21.78k | -5.29m | 104.71m | 40.00 | -- | 6.03 | -- | 4,807.02 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Heidelberg Pharma AG | 9.52m | -13.06m | 109.52m | 97.00 | -- | 2.66 | -- | 11.50 | -0.2837 | -0.2837 | 0.2062 | 0.8832 | 0.1270 | 0.194 | 13.23 | 100,234.60 | -17.42 | -43.91 | -22.34 | -64.34 | 82.74 | 52.13 | -137.16 | -206.24 | 4.90 | -- | 0.3417 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| BenevolentAI SA | 5.81m | -61.35m | 111.26m | 248.00 | -- | 1.13 | -- | 19.15 | -0.5111 | -0.5111 | 0.0484 | 0.6886 | 0.0401 | -- | 0.1712 | 23,425.98 | -42.37 | -- | -50.50 | -- | -14.73 | -- | -1,056.02 | -- | -- | -- | 0.0594 | -- | -30.58 | -- | 61.38 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 8.27m | -26.10m | 118.25m | 32.00 | -- | 3.34 | -- | 14.30 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -18.91m | 118.76m | 26.00 | -- | 2.48 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Oryzon Genomics SA | 0.00 | -3.82m | 119.24m | 43.00 | -- | 1.34 | -- | -- | -0.0597 | -0.0597 | 0.00 | 1.37 | 0.00 | 153.65 | -- | 0.00 | -3.55 | -4.20 | -4.13 | -4.82 | -- | -- | -- | -- | 0.9495 | -3.54 | 0.134 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
| Diamyd Medical AB | 16.38k | -12.29m | 123.46m | 25.00 | -- | 7.39 | -- | 7,537.94 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Futura Medical PLC | 10.02m | -4.48m | 129.33m | 12.00 | -- | 13.88 | -- | 12.90 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Nightingale Health Oyj | 3.65m | -18.06m | 133.33m | 81.00 | -- | 2.22 | -- | 36.49 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Transgene SA | 7.63m | -22.33m | 137.32m | 158.00 | -- | 6.69 | -- | 17.99 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Vicore Pharma Holding AB | 9.18m | -17.62m | 138.13m | 28.00 | -- | 1.85 | -- | 15.05 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Nanoform Finland Oyj | 2.29m | -21.67m | 140.10m | 174.00 | -- | 1.98 | -- | 61.06 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Cellectis SA | 17.59m | -88.46m | 141.88m | 235.00 | -- | 1.06 | -- | 8.07 | -1.39 | -1.11 | 0.2345 | 1.86 | 0.0619 | -- | 3.86 | 74,855.30 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Data as of Sep 20 2024. Currency figures normalised to Oryzon Genomics SA's reporting currency: Euro EUR
0.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 141.28k | 0.22% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 66.56k | 0.10% |
| Santander Private Banking Gestion SA SGIICas of 30 Jun 2024 | 50.00k | 0.08% |
| Tressis Gesti�n SGIIC SAas of 30 Jun 2024 | 45.00k | 0.07% |
| Solventis SGIIC SAas of 30 Jun 2024 | 20.00k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 30 Jun 2024 | 12.40k | 0.02% |
| Gesiuris Asset Management SGIIC SAas of 30 Jun 2024 | 8.00k | 0.01% |
| Gesti�n de Patrimonios Mobiliarios AV SAas of 30 Jun 2024 | 4.00k | 0.01% |
| Gescooperativo SA SGIICas of 30 Jun 2024 | 3.92k | 0.01% |
| Andbank Wealth Management SGIIC SAUas of 30 Jun 2024 | 200.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
